Genomic medicine: Health care issues and the unresolved ethical and social dilemmas

American Journal of Therapeutics

Volumn 21, Issue 6, 2012, Pages 548-553

  Idemyor, Vincent ^a,b  

^a UNIVERSITY OF PORT HARCOURT   (Nigeria)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Genetics; Genomics; Pharmacogenomics

Indexed keywords

ARTICLE; DISEASE PREDISPOSITION; ETHNIC OR RACIAL ASPECTS; GENOMICS; HEALTH CARE; HEALTH INSURANCE; MEDICAL ETHICS; MEDICAL PROFESSION; MEDICINE; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SOCIAL STIGMA; TREATMENT RESPONSE;

EID: 84862275950     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3182583bd1     Document Type: Article

References (42)

1. Hughes HB, Biehl JP, Jones AP, et al. Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am Rev Tuberc. 1954;70:266-273.
2. Carson PE, Flanagan CL, Ickes CE, et al. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956;124:484-485.
3. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960;2:485-491.
4. A haplotype map of the human genome. Nature. 2005;437: 1299-1320.
5. Sachidanandam R,Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001; 409:928-933.
6. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545-556.
7. Kamisago M, Sharma SD, DePalma SR, et al. Mutations in sarcmere protein genes as a cause of dilated cardiomyopathy. N Engl J Med. 2000;343:1688-1696.
8. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 2001;104: 569-580.
9. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805-811.
10. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392:293-296.
11. Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet. 1999;23:20-21.
12. Hudson TJ, Anderson W, Artez A, et al. International networks of cancer genome projects. Nature. 2010;464: 993-998.
13. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia [abstract]. Science. 1960;132:1497. Abstract.
14. Nusbaum R, Isaacs C. Management updates for women with a BRCA1 or BRCA2 mutation. Mol Diagn Ther. 2007; 11:133-144.
15. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B∗5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727-732.
16. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121-1122.
17. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B∗5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004;101:4180-4185.
18. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004;5:203-211.
19. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19:979-981.
20. Mallal S, Phillips E, Carosi G, et al. HLA-B∗5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358: 568-579.
21. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;11:1240-1243.
22. Olsson R, Wiholm BE, Sand C, et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol. 1992; 15:154-161.
23. Fairley CK, McNeil JJ, Desmond P, et al. Risk factors for the development of flucloxacillin associated jaundice. BMJ. 1993;306:233-235.
24. [Erratum in: BMJ. 1993;307:1179].
25. Russmann S, Kaye JA, Jick SS, et al. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol. 2005;60:76-82.
26. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816-819.
27. Cappellini MD, Fiorelli G: Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64-74.
28. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100-1104.
29. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to peggylated interferon-alpha and ribavirn therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.
30. Maddox J. New genetics means no new ethics. Nature. 1993;364:97.
31. Kegley JA. Using genetic information: the individual and the community. Med Law. 1996;15:377-389.
32. Clayton EW. Ethical, legal, and social implications of genomic medicine. N Engl J Med. 2003;349:562-568.
33. O'Neill O. Genetic information and insurance: some ethical issues. Philos Trans R Soc Lond B Biol Sci. 1997;352: 1087-1093.
34. Freedman BI. End-stage renal failure in African Americans: insights in kidney disease susceptibility. Nephrol Dial Transplant. 2002;17:198-200.
35. Yancy CW, Hajjar RJ, MacRae CA. Adrenergic-receptor polymorphisms and heart failure. N Engl J Med. 2002;347: 1196-1199.
36. Henderson SO, Coetzee GA, Ross RK, et al. Elevated mortality rates from circulatory disease in African American men and women of Los Angeles County, California-a possible genetic susceptibility? Am J Med Sci. 2000;320:18-23.
37. Kidd JM, Cooper GM, Donahue WF, et al. Mapping and sequencing of structural variation from eight human genomes. Nature. 2008;453:56-64.
38. Feero WG, Guttmacher AE, Collins FS. Genomic medicine-an updated primer. N Engl J Med. 2010;362: 2001-2011.
39. Burchard ES, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical Practice. N Engl J Med. 2003;348:1170-1175.
40. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002;296: 2225-2229.
41. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest. 2008;118:1590-1605.
42. Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011;364:1144-1153.